In this article, we explain a pharmacogenetics approach which allows to selectively and reversibly inactivate LC neurons using Designer Receptors Exclusively Activated by Designer Prescription drugs (DREADD). We demonstrate which the expression with the hM4Di DREADD is usually restricted to noradrenergic LC neurons Which the amount of LC inhibition